Cranberry extracts promote growth of Bacteroidaceae and decrease abundance of Enterobacteriaceae in a human gut simulator model.
Bacteroidaceae
/ drug effects
Enterobacteriaceae
/ drug effects
Escherichia coli
/ drug effects
Gastrointestinal Microbiome
/ drug effects
Humans
Hydroxybenzoates
/ pharmacology
Microbial Sensitivity Tests
Models, Biological
Plant Extracts
/ pharmacology
Powders
Salicylic Acid
/ pharmacology
Urinary Tract Infections
/ microbiology
Vaccinium macrocarpon
/ chemistry
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
17
05
2019
accepted:
22
10
2019
entrez:
13
11
2019
pubmed:
13
11
2019
medline:
21
3
2020
Statut:
epublish
Résumé
The opportunistic pathogen Escherichia coli, a common member of the human gut microbiota belonging to the Enterobacteriaceae family, is the causative agent of the majority of urinary tract infections (UTIs). The gut microbiota serves as a reservoir for uropathogenic E. coli where they are shed in feces, colonize the periurethral area, and infect the urinary tract. Currently, front line treatment for UTIs consists of oral antibiotics, but the rise of antibiotic resistance is leading to higher rates of recurrence, and antibiotics cause collateral damage to other members of the gut microbiota. It is commonly believed that incorporation of the American cranberry, Vaccinium macrocarpon, into the diet is useful for reducing recurrence of UTIs. We hypothesized such a benefit might be explained by a prebiotic or antimicrobial effect on the gut microbiota. As such, we tested cranberry extracts and whole cranberry powder on a human gut microbiome-derived community in a gut simulator and found that cranberry components broadly modulate the microbiota by reducing the abundance of Enterobacteriaceae and increasing the abundance of Bacteroidaceae. To identify the specific compounds responsible for this, we tested a panel of compounds isolated from cranberries for activity against E. coli, and found that salicylate exhibited antimicrobial activity against both laboratory E. coli and human UTI E. coli isolates. In a gut simulator, salicylate reduced levels of Enterobacteriaceae and elevated Bacteroidaceae in a dose dependent manner.
Identifiants
pubmed: 31714906
doi: 10.1371/journal.pone.0224836
pii: PONE-D-19-14052
pmc: PMC6850528
doi:
Substances chimiques
Hydroxybenzoates
0
Plant Extracts
0
Powders
0
beta-resorcylic acid
LU39SC9JYL
Salicylic Acid
O414PZ4LPZ
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0224836Déclaration de conflit d'intérêts
Ocean Spray Cooperatives provided funding for this work. HL and CK are paid employees of Ocean Spray Cooperative; HL and CK provided cranberry materials and cranberry material methodology for this manuscript and contributed to the initial conceptualization, but HL and CK did not have any role in data collection and analysis or decision to publish. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
Front Med (Lausanne). 2015 Apr 30;2:26
pubmed: 25984513
Nature. 2012 Jun 13;486(7402):207-14
pubmed: 22699609
Pathogens. 2016 Mar 15;5(1):
pubmed: 26999218
J Med Chem. 2016 Oct 27;59(20):9390-9408
pubmed: 27689912
Front Microbiol. 2017 Apr 04;8:542
pubmed: 28421045
Nat Immunol. 2010 May;11(5):373-84
pubmed: 20404851
J Agric Food Chem. 2005 Apr 20;53(8):2897-900
pubmed: 15826036
Cell Host Microbe. 2009 Jun 18;5(6):522-6
pubmed: 19527880
Nature. 2017 Jun 22;546(7659):528-532
pubmed: 28614296
Immunity. 2012 Jul 27;37(1):158-70
pubmed: 22705104
Science. 2013 Feb 8;339(6120):708-11
pubmed: 23393266
Infect Immun. 2012 Jan;80(1):62-73
pubmed: 22006564
Appl Microbiol Biotechnol. 1993 May;39(2):254-8
pubmed: 7763732
Cell. 2009 Oct 30;139(3):485-98
pubmed: 19836068
Nat Commun. 2014 Aug 28;5:4714
pubmed: 25163406
Pediatr Res. 2015 Jan;77(1-2):236-44
pubmed: 25314581
Mucosal Immunol. 2017 Jan;10(1):18-26
pubmed: 27554295
Nat Rev Microbiol. 2015 May;13(5):269-84
pubmed: 25853778
Clin Pharmacokinet. 1985 Mar-Apr;10(2):164-77
pubmed: 3888490
Antimicrob Agents Chemother. 2017 Mar 24;61(4):
pubmed: 28137805
Nature. 2009 Apr 30;458(7242):1191-5
pubmed: 19252480
EMBO Rep. 2013 Apr;14(4):319-27
pubmed: 23478337
Nat Neurosci. 2017 Feb;20(2):145-155
pubmed: 28092661
Nat Immunol. 2013 Jul;14(7):676-84
pubmed: 23778795
Nat Rev Urol. 2010 Dec;7(12):653-60
pubmed: 21139641
Cochrane Database Syst Rev. 2012 Oct 17;10:CD001321
pubmed: 23076891
Nat Microbiol. 2019 Mar;4(3):396-403
pubmed: 30531975
J Urol. 1997 Mar;157(3):1127-9
pubmed: 9072556